CJC-1295

Quick Summary

CJC-1295 is a synthetic analogue of the active 1–29 fragment of human growth hormone-releasing hormone (GHRH). The version studied most clearly in humans includes a Drug Affinity Complex, or DAC, that binds to circulating albumin and markedly extends exposure. Published human research shows that this DAC form can increase measured growth hormone (GH) and insulin-like growth factor 1 (IGF-1) for several days. Those biochemical outcomes should not be presented as proof of long-term fat loss, muscle gain, recovery, sleep improvement or anti-aging benefit.

Identity and Aliases

The name CJC-1295 is used inconsistently online. Technically, CJC-1295 refers to the modified GHRH analogue developed with an albumin-binding DAC group. Vendors also use “CJC-1295 without DAC” for Modified GRF (1-29), a shorter-acting molecule that lacks the albumin-binding modification. The two forms should not be treated as interchangeable in evidence summaries because the strongest human pharmacokinetic data concern the DAC form.

Position in the GH–IGF-1 Axis

GHRH is released by the hypothalamus and activates receptors on pituitary somatotroph cells. This signal promotes secretion of GH, which in turn stimulates hepatic production of IGF-1. CJC-1295 acts upstream at the GHRH receptor. It does not supply exogenous GH and it is not an IGF-1 product.

Human Evidence

In randomized, placebo-controlled studies of healthy adults, CJC-1295 produced dose-dependent increases in mean GH concentrations and sustained increases in IGF-1. The widely cited Teichman study reported mean GH increases of roughly two- to ten-fold for six days or longer and mean IGF-1 increases of approximately 1.5- to three-fold for nine to eleven days. The estimated half-life was measured in days. These trials were designed around pharmacokinetics, hormonal markers and short-term safety. They were not large, long-duration outcome trials for obesity, athletic performance, aging or recovery.

DAC and No-DAC Evidence

The DAC group enables covalent albumin binding and prolonged circulation. The term “CJC-1295 no DAC” is commonly used for Modified GRF (1-29), but dedicated human outcome evidence for that marketed form is sparse. Claims about no-DAC schedules or superiority often come from mechanism, community practice or extrapolation rather than direct comparative trials.

Safety and Regulatory Status

CJC-1295 is not an FDA-approved drug. FDA public compounding materials state that compounded CJC-1295 may present immunogenicity and peptide-impurity concerns and note serious adverse events including increased heart rate and systemic vasodilatory reactions. Available clinical data remain limited. A disclaimer does not convert an unapproved product into an approved medicine.

Sports Status

The World Anti-Doping Agency lists CJC-1295 among growth hormone-releasing hormone analogues prohibited under section S2. Athletes subject to testing should not rely on “research use” labels or supplement marketing when evaluating anti-doping risk.

Evidence Gaps

• No approved therapeutic indication.
• No large long-term trial demonstrating general anti-aging benefit.
• No dedicated clinical trial establishing outcomes for the CJC-1295 and Ipamorelin combination.
• Limited direct evidence for products marketed as CJC-1295 without DAC.

Primary References

• Teichman SL et al. Human pharmacokinetic and pharmacodynamic study of CJC-1295.
• FDA: bulk drug substances that may present significant safety risks.
• WADA Prohibited List.